Tuesday, October 13, 2026

NeuroMetrix Already 5% Up, Almost Four Hours Before The NASDAQ Open

NeuroMetrix Already 5% Up, Almost Four Hours Before The NASDAQ Open

(VIANEWS) - The NASDAQ opens in less than four hours and NeuroMetrix's pre-market value is already 5.63% up.

NeuroMetrix's last close was $1.42, 75.89% under its 52-week high of $5.89.

The last session, NASDAQ ended with NeuroMetrix (NURO) dropping 0% to $1.42. NASDAQ fell 1.98% to $11,799.16, after two consecutive sessions in a row of losses, on what was an all-around bearish trend trading session.

About NeuroMetrix

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.62.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -18.97%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1.5%, now sitting on 8.26M for the twelve trailing months.

Yearly Top and Bottom Value

NeuroMetrix's stock is valued at $1.42 at 05:48 EST, way below its 52-week high of $5.89 and higher than its 52-week low of $1.33.

Volume

Today's last reported volume for NeuroMetrix is 13565 which is 69.35% below its average volume of 25196.

More news about NeuroMetrix (NURO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com